93% overall response and 76% complete response rates with median progression-free survival of 18 months in patients with large B-cell…
Dévoilement de la politique bioalimentaire 2025-2035 August 22, 2025 12:52 ET | Source: Collectif Vital MONTRÉAL, Aug. 22, 2025 (GLOBE…
July 13, 2025 17:45 ET | Source: Crinetics Pharmaceuticals, Inc. Data show that PALSONIFY was well tolerated and IGF-1 levels…
SAN FRANCISCO, July 11, 2025 (GLOBE NEWSWIRE) -- Neurona Therapeutics, a clinical-stage biotherapeutics company advancing regenerative cell therapies for disorders…
Results from the Phase 2 RedirecTT-1 study demonstrate deep responses with 78.9 percent overall response rate through dual targeting of…